IBI Seminar: Dr. Bin Chen, PhD
May 11 @ 10:00 am - 11:00 am
“Leveraging molecular and clinical data to transform cancer drug discovery in the era of precision medicine”
Bin Chen, PhD
Department of Pediatrics and Institute for Computational Health Sciences
University of California, San Francisco
Thursday, May 11, 2017
Rapidly decreasing costs of molecular measurement technologies not only enable profiling of disease sample molecular features at different levels (e.g., transcriptome, proteome, metabolome), but also enable measuring of cellular signatures of individual drugs in clinically relevant models. Exploring systematic approaches to find drugs for diseases through various molecular features is critically important in the discovery of new therapeutics. We propose a systems-approach to identifying drugs that reverse the molecular state of a disease. Using this approach, we have identified drug candidates for hepatocellular carcinoma (Gastroenterology, 2017) and Ewing’s sarcoma (Oncotarget, 2017). Our recent pan-cancer analysis indicates that the ability to reverse cancer gene expression correlates to drug efficacy (Nature Communications, accepted). I will argue that this approach may be complementary to the traditional target-based approach and holds a great promise in guiding personalized cancer therapy.